Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Dasatinib|DRUG: Ixabepilone
Sponsor: Accelerated Community Oncology Research Network
Collaborators: Bristol-Myers Squibb